Shiyi Yang
Southwest Petroleum University(CN)
Publications by Year
Research Areas
Multiple Myeloma Research and Treatments, Gene expression and cancer classification, Monoclonal and Polyclonal Antibodies Research, Chronic Lymphocytic Leukemia Research, Single-cell and spatial transcriptomics
Most-Cited Works
- → Talquetamab, a T-Cell–Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma(2022)599 cited
- → Decontamination of ambient RNA in single-cell RNA-seq with DecontX(2020)586 cited
- → Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: a pooled analysis from three open‐label studies(2017)141 cited
- → Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES): an open‐label Phase II study(2020)61 cited
- → Updated Phase 1 Results from MonumenTAL-1: First-in-Human Study of Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma(2021)51 cited
- → Celda: a Bayesian model to perform co-clustering of genes into modules and cells into subpopulations using single-cell RNA-seq data(2022)39 cited
- → Efficacy and safety of talquetamab, a G protein-coupled receptor family C group 5 member D x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM): Updated results from MonumenTAL-1.(2022)27 cited
- → Daratumumab (DARA) with Bortezomib, Thalidomide, and Dexamethasone (VTd) in Transplant-Eligible Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM): Analysis of Minimal Residual Disease (MRD) Negativity in Cassiopeia Part 1 and Part 2(2021)20 cited
- → The Mutational Signature Comprehensive Analysis Toolkit (musicatk) for the Discovery, Prediction, and Exploration of Mutational Signatures(2021)19 cited